Eleva Capital’s Viridian Therapeutics VRDN Stock Holding History

Eleva Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-7,126	Closed	-$139K	–	42
2026 Q2	$139K	Hold	7,126	–	–	0.04%	20
2026 Q1	$139K	Buy	+7,126	New	+$212K	0.04%	20

Other funds holding VRDN

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Eleva Capital's VRDN Position: Q3 2026 in Review

Eleva Capital sold out of Viridian Therapeutics (VRDN) in Q3 2026, closing a stake of 7,126 shares — an estimated $139K sold.

Eleva Capital first reported a position in VRDN in Q1 2026 and held it in 2 quarters. The position peaked at $139K in Q2 2026. 1 fund tracked by Wall St. Rank holds VRDN as of Q3 2026.

Eleva Capital reported no remaining Viridian Therapeutics position as of Q3 2026 after selling out during the quarter.
Eleva Capital sold 7,126 Viridian Therapeutics shares in Q3 2026, an estimated $139K.
Eleva Capital first reported a position in Viridian Therapeutics in Q1 2026 and held it in 2 quarters.
Eleva Capital's Viridian Therapeutics position peaked at $139K in Q2 2026.
1 fund tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Eleva Capital's 13F filing for Q3 2026, filed 6 Oct 2026.